SUPPORTING INFORMATION
. Diffusion coefficients and dimer off-rates for HA-EGFR-WT, HA-EGFR-L858R, and HA-EGFR-ΔL747-P753insS. Dimer off-rates (K off,dimer ) and error estimates (K off,dimer Error) are calculated using Hidden Markov Model analysis (Low-Nam et al., 2011) .
Diffusion results are shown in Figure 2 F-H, and dimerization results are shown in Figure 2 A-E. Shown are the donor (Oregon Green 488) fluorescence lifetime values, τ 2 , for EGFR-WT and EGFR-L858R alone (Donor), with NR12 acceptor (Donor + Acceptor), or in the presence of 30 nM EGF (Donor + Acceptor + EGF).
The fluorescence lifetime error (τ 2 error) represents the s.e.m. for the total number of cells (n) acquired for several independent experiments over multiple days.
See Figure 1C . In the presence of saturating concentration of EGF, receptor phosphorylation is independent of expression level, shown as a linear increase in phosphorylation v. receptor expression. This is consistent with previous reports of wild type EGFR (Endres et al., 2013) . Note that EGF-induced phosphorylation is lower in EGFR mutants. 
Supplementary Note -Description and discussion of the model
The data of Figure 1C reveal differences between EGFR-WT and mutant forms in their dependence of phospho-EGFR level on total EGFR level. We considered two possible explanations for these differences: (1) differences in intrinsic kinase activity and (2) differences in receptor dimerization affinity. Mathematical models were developed that incorporate these explanatory mechanisms (Models 1 and 2) and these models (and generalizations) were used to analyze the data. As discussed in the main text, both models are consistent with the data (Fig.   1C ). According to Model 1, where dimerization affinity is assumed to be the same for each species, EGFR-L858R has higher kinase activity than EGFR-ΔL747-P753insS, which in turn has higher kinase activity than EGFR-WT. In contrast, according to Model 2, where intrinsic kinase activity is assumed the same for each species, EGFR-L858R dimerizes more readily than EGFR-ΔL747-P753insS, which in turn dimerizes more readily than EGFR-WT.
The simplest model for monomer-dimer equilibrium
Models 1 and 2 are special cases of a more general model, which can be derived for diverse receptor dimerization mechanisms. The simplest mechanism is MX + MX = DX, where MX is an EGFR monomer of form X (X = WT, ΔL747-P753insS or L858R) and DX is a homodimer of EGFR-X (i.e. dimeric EGFR-WT, EGFR-ΔL747-P753insS or EGFR-L858R). For this mechanism, at equilibrium (or more generally at steady state where detailed balance holds (Gorban and Yablonsky, 2011) 
The general model, from which Models 1 and 2 derive, is based not only on the above considerations but also on a measurement model, i.e., transformations (functions) that relate measured fluorescence intensities, which are recorded in arbitrary units (a.u.) that depend on instrument settings, to the variables in Eqs.
(1) and (2), meaning the abundances of monomers, dimers, and total receptor.
The measurement model is obtained by assuming that fluorescence intensities measured in immunofluorescence assays of phosphorylated EGFR-X and total EGFR-X levels, denoted FP,X and FR,X, are linearly related to [MX] , [DX] , and [RT,X] as follows:
FR,X = aR[RT,X] + bR,X
where bP,X and bR,X are background fluorescence levels (a.u.) matched to receptor form X (because the behavior of each receptor form was characterized by an independent series of immunofluorescence assays, all performed on the same day with the same instrument settings); aP,X is an intensive parameter reflecting the average contribution of a dimer of receptors of form X to the fluorescence intensity FP,X; μX is a dimensionless ratio of intensive parameters that reflects the average contribution of a receptor monomer of form X to the fluorescence intensity FP,X relative to that of a receptor dimer; and aR is an intensive parameter, taken to be independent of receptor form X, reflecting the contribution of each receptor, whether in a monomeric or dimeric state, to the fluorescence intensity FR,X. We consider aP,X (and μX) to depend on receptor form because the different receptor forms potentially have different intrinsic kinase activities.
Indeed, differences in kinase activities have been reported for EGFR-L858R (Zhang et al., 2006) . Recall that the mutations being considered affect the kinase domain of EGFR. Because EGFR autophosphorylation depends on receptor dimerization and basal phosphatase activity is high (Kleiman et al., 2011) , we expect μX to be small. We allow for a non-zero value because phosphorylated receptors leaving dimers can be expected to remain phosphorylated for some finite amount of time (Verveer et al., 2000; Sawano et al., 2002; Reynolds et al., 2003) . We assume that aR is independent of receptor form because the labeling antibody used in immunofluorescence assays is expected to recognize all receptor forms under consideration without distinction. Recall that bR,X corresponds to the value of FR,X for a cell expressing no EGFR-X (Eq. (4)), assuming even moderate levels of average EGFR expression we expect bR,X to be negligible.
From Eqs. (1)- (4), we obtain the following equations, which characterize the equilibrium or steady-state dependence of FP,X on FR,X for each receptor form X:
FP,X = bP,X + (aP,X/aR)(aR×KD,X)(μX×NX/4 + NX 
where NX = (1 + 8(FR,X -bR,X)/(aR×KD,X))
We used these equations for each X (WT, ΔL747-P753insS and L858R) to analyze the data of Figure 1C , focusing on two simplifications: Models 1 and 2.
Model 1 is derived from Eqs. (5) and (6) by setting μX = 0 and bR,X = 0 for each X (as a simplification) and by requiring that the (apparent) equilibrium dissociation constants for the different receptor forms be the same: KD,WT = KD,ΔL747-P753insS = KD,L858R = KD. In Model 1, the ratios aP,WT/aR, aP,ΔL747-P753insS/aR and aP,L858R/aR, which reflect the intrinsic kinase activities of the different receptor forms, are allowed to have different values. Model 2 is derived from Eqs. (5) and (6) (Fig. 1C) . We assume that the non-zero background reflects a combination of non-specific antibody binding and/or microscope acquisition settings.
To estimate the values of the free parameters of Models 1 and 2, we used chi-square fitting, which is also known as weighted nonlinear least squares fitting. Minimal values of the chi-square function, which is discussed below, were found via the modified LevenbergMarquardt algorithm implemented in LMDIF (Moré et al., 1980) with the following input settings: FTOL = XTOL = GTOL = 10 -15
, MAXFEV = 1000, EPSFCN = 0.1, MODE = 1, FACTOR = 1, and NPRINT = 0. In fitting, we considered all of the data shown in Fig. 1C together. In other words, our best-fit parameter estimates represent the results of a global fit. The data in Figure 1C summarize more than 500 pairs of fluorescence intensity measurements from three series of This function has one receptor form X-independent parameter (m) and one receptor form Xspecific parameter (bX), which were set at the following values: m = 0.0042, bWT = 1.35, bΔL747-P753insS = 2.37, and bL858R = 2.775.
We found 68% confidence limits on parameter estimates through bootstrapping, which involved repeated fitting to samples of the original data (Efron and Tibshirani, 1994; Press et al., 2007) . Sampling (with replacement) has the effect of randomly assigning weights to the data points. For each determination of a confidence limit, we considered 10,000 bootstrap samples of the data. Fitting was performed as described above. Each fitting run began with randomly selected starting values for the free parameters, i.e., at a randomly selected point in parameter space. Fitting runs sometimes failed to converge (i.e., LMDIF terminated before satisfaction of a convergence test). In these cases, fitting was simply restarted from a new randomly selected at convergence, the results were rejected (under the assumption that the fitting routine converged to a local minimum far from the global minimum) and fitting was restarted from a new randomly selected point in parameter space. In the vast majority of cases, the final accepted χB was close to χ.
Although Models 1 and 2 both reasonably fit the data (Fig. 1C) , the two models make distinct predictions about the extent of dimerization as a function of total receptor abundance, as can be seen in Figure S10 . We note that Models 1 and 2 provide explanations of the data at opposite extremes. Phosphorylation differences are explained by kinase activity differences alone in the case of Model 1 and dimerization affinity differences alone in the case of Model 2.
Because both models explain the data of Figure 1C , it is conceivable that the altered phosphorylation of EGFR mutants and the observed differences in dependence of phospho-EGFR level on total EGFR expression may arise from a combination of both kinase activity and dimerization differences.
As discussed above, Models 1 and 2 are based on certain assumptions that constrain the values of the parameters in Eqs. (5) and (6). One assumption that is common to both models is that monomeric receptors contribute negligibly to the observed phosphorylation signal. To assess this assumption, we allowed non-zero values for μWT, μΔL747-P753insS and μL858R, obtaining an extension of Model 1 (Extended Model 1), and a non-zero value for μ (= μWT = μΔL747-P753insS = μL858R), obtaining an extension of Model 2 (Extended Model 2). We then estimated parameters and confidence limits as described above for Extended Models 1 and 2. The results, which are given in Table S4 , indicate that monomers, as expected, contribute much less to observed receptor phosphorylation than dimers. Quality of fit is not dramatically improved by accounting for monomer phosphorylation. The most improvement in quality of fit is obtained for the EGFR-WT data when considering Extended Model 2. Figure S10. This figure displays the same information as Fig. 1C , except that fluorescence intensity measurements and calculated values for F R,X and F P,X (Eqs. (5) and (6)) have been transformed using Eqs. (3) and (4) and the values of a P,X and b P,X determined for (A) Model 1 and (B) Model 2. The horizontal axis reports F R,X /<F R,X > = [R T,X ]/[R T,X ] 0 , where <F R,X >=40.77 (a.u.) is the mean labeling intensity of EGFR-X and [R T,X ] 0 is the corresponding (unknown) EGFR-X copy number, for EGFR-WT data (black circles), EGFR-ΔL747-P753insS (blue circles), and EGFR-L858R data (red circles). The vertical axis reports 2(F P,X -b P,X )/((a P,X /a R )<F R,X >) = 2[D X ]/[R T,X ] 0 (i.e., the relative number of receptors in dimers). The curves shown in the top and bottom panels are obtained from Eqs. (5) and (6) and the parameter values given in Table S3 .
The equivalence of various equilibrium models for ligandindependent dimerization of EGFR 1 The simplest model for monomer-dimer equilibrium
Consider the following reaction scheme:
where M represents a receptor monomer and D represents a receptor dimer. At equilibrium,
where K is the equilibrium association constant and M and D now represent abundances.
Assuming conservation of receptor, we have
where R T is the total abundance of receptor. Solving the quadratic equation
From Eqs. (8) and (10), we find
Let us assume linear relationships between abundances and fluorescence intensities, such that
and
where F P is the fluorescence intensity of anti-pY, F R is the fluorescence intensity of anti-EGFR, b P and b R are background intensities, and a P , a P , and a R are scaling factors. In Eq. (12), the terms a P D and a P M reflect the contributions of dimers and monomers, respectively, to the anti-pY fluorescence intensity. Rearranging, we find
where K D ≡ 1/K is the equilibrium dissociation constant, µ ≡ a P /a P , and
In the above equations, there are only five identifiable parameters that relate F P and F R , namely, b P , b R , a P /a R , µ, and a R K D .
A model that accounts for two receptor dimerization interfaces and EGFR oligomers up to cyclic receptor dimers
where M represents a receptor monomer, D x represents a receptor dimer connected via an ectodomain interface, D y represents a receptor dimer connected via an endodomain interface, and D xy represents a (cyclic) receptor dimer connected via both ecto-and endodomain interfaces. We neglect higher-order EGFR oligomers. At equilibrium,
where K x is an equilibrium association constant that characterizes the ectodomain interface; K y is an equilibrium association constant that characterizes the endodomain interface; J x and J y are equilibrium constants that characterize cycle formation; and M , D x , D y , and D xy now represent abundances. For consistency with the principle of detailed balance, the following constraint must be satisfied:
Let us introduce the following definitions:
From Eqs. (17) and (19), it follows that
For conservation of receptor, we have
where R T is the total abundance of receptor. As before, we take F P to be linearly related to the abundances of EGFR monomers and dimers and F R to be linearly related to the total abundance of EGFR (Eqs. (12) and (13)). Furthermore, as in the simplest model (Section 1), we have the following relations: R T = M + 2D and D = KM 2 . Thus, under the assumption of Eq. (16) instead of Eq. (7), Eqs. (14) and (15) given earlier can be used to relate F P and F R with reinterpretation of the parameters. For example, K D in Eqs. (14) and (15) is now taken to be a function of the equilibrium constants that parameterize the reaction scheme of Eq. (16): 3 A model that accounts for tethered and extended conformations of monomeric EGFR and one dimerization interface
where M e represents a receptor monomer in an extended conformation, M t represents a receptor monomer in tethered conformation, and D represents a receptor dimer. We assume that only extended receptors are competent for dimerization. At equilibrium,
where K 0 is an equilibrium constant that characterizes the equilibrium distribution of receptor monomers into tethered and extended forms and K 1 is an equilibrium association constant that characterizes dimerization of monomers in the extended conformation. For conservation of receptor, we have
where R T is the total abundance of receptor and M ≡ M e + M t is the abundance of receptor monomer (in either conformation). Let us introduce the following definitions:
where f e (f t ) is the fraction of receptor monomers in the extended (tethered) conformation at equilibrium. With these definitions, it follows that R T = M + 2D and D = KM 2 . These relationships are consistent with those derived from the reaction scheme of Eq. (7) (Section 1). Thus, we can relate F P and F R using Eqs. (14) and (15) with reinterpretation of the parameters. For example, we now interpret K D in these equations as a function of the equilibrium constants that parameterize the reaction scheme of Eq. (22):
Throughout the discussion above, we have assumed that fluorescence intensities are related to model variables in accordance with Eqs. (12) and (13), which were derived within the context of the simplest model for monomer-dimer equilibrium (Section 1). Here, we will generalize the first of these equations, considering the possibility that monomeric and dimeric receptors in distinct states contribute differentially to the anti-pY fluorescence intensity, F P . Let us focus on the model of Section 4, which considers two types of monomeric receptors (i.e., monomers in extended and tethered conformations) and three types of dimeric receptors (i.e., dimers connected via an ectodomain interface only, dimers connected via an endodomain interface only, and dimers connected via both ectodomain and endodomain interfaces). We will assume that a linear relationship exists between the abundance of a molecular species and its contribution to the total fluorescence intensity. Thus, we have F P = a P,x D x + a P,y D y + a P,xy D xy + a P,e M e + a P,t M t + b P
where b P is the background fluorescence intensity and a P,x , a P,y , a P,xy , a P,e , and a P,t are scaling factors. Each factor determines how the abundance of a molecular species contributes to the total fluorescence intensity F P . We will show that Eq. (37) reduces to a form identical to that of Eq. (12). In this demonstration, we will use the following relations, which follow from the results presented in Section 4:
The above relations allow us to rewrite Eq. (37) as follows:
F P = [(a P,x K x +a P,y K y +a P,xy φ)/(K x +K y +φ)]D+[(a P,e +a P,t K 0 )/(1+K 0 )]M +b P (39)
Simplifying, we obtain an expression that has the same form as Eq. (12):
whereâ P = a P,x K x + a P,y K y + a P,xy φ K x + K y + φ
andâ P = a P,e + a P,t K 0 1 + K 0
As can be seen from Eqs. (41) and (42), the parametersâ P andâ P in Eq. (40) are weighted sums of scaling factors that appear in Eq. (37). Each weight is a function of one or more equilibrium constants. Importantly, the values ofâ P andâ P are not determined by the value K D (Eq. (31)), i.e., these parameters can be estimated independently.
Measured fluorescence intensities of anti-pY and anti-EGFR can be related using Eqs. (14) and (15) for a variety of ligand-independent receptor dimerization mechanisms. However, the interpretation of the parameter K D in these equations depends on the reaction scheme being considered. In the simplest scheme, that of Section 1, K D is simply the equilibrium dissociation constant for receptor dimerization. In a more complicated scheme (Sections 2-5), K D is an apparent equilibrium constant, which is a function of multiple equilibrium constants.
A limitation of the analysis summarized here is that we have neglected oligomers of EGFR larger than dimers. Reaction schemes that describe higher-order oligomer formation would require modification of Eqs. (14) and (15). We are essentially assuming that in the absence of ligand the predominant EGFR oligomer is a dimer. This assumption in not necessarily incompatible with ligand-induced formation of higher-order oligomers.
